Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.

This article presents an overview of preclinical studies and clinical trials of a number of independently derived farnesyltransferase inhibitors (FTIs). Potential targets and biological modes of action of FTIs are discussed, and the results of clinical trials are summarized. The significant efficacy of FTIs as single or combined agents in preclinical studies stands in contrast with only moderate effects in clinical Phase II-III trials. These results reveal a substantial gap in the understanding of the complex activity of FTIs and their interactions with cytotoxic agents. We conclude that the rational combination of FTIs with other therapies, taking into account the biological activities of the individual agents, may improve the clinical results obtained with FTIs.

[1]  M. Dowsett,et al.  Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Marks,et al.  Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Sebastian Maurer-Stroh,et al.  Protein prenyltransferases , 2003, Genome Biology.

[4]  Hao Wang,et al.  Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Maurer-Stroh,et al.  Protein Prenyltransferases: Anchor Size, Pseudogenes and Parasites , 2003, Biological chemistry.

[6]  Stephen S. Taylor,et al.  Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. , 2002, Journal of cell science.

[7]  Theresa M. Grana,et al.  Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. , 2002, Cancer research.

[8]  C. Fuchs,et al.  Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. , 2002, Molecular cancer therapeutics.

[9]  S. Sebti,et al.  The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status , 2002, Cell Death and Differentiation.

[10]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[11]  J. B. Sajous,et al.  Ras signalling on the endoplasmic reticulum and the Golgi , 2002, Nature Cell Biology.

[12]  S. Hahn,et al.  A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  R. Weber,et al.  Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  M. Lindstrom,et al.  Advances in Brief Regions of Hand KRas That Provide Organ Specificity / Potency in Mammary Cancer Induction 1 , 2002 .

[15]  G. Prendergast,et al.  Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. , 2002, Cancer research.

[16]  J. Hancock,et al.  The Linker Domain of the Ha-Ras Hypervariable Region Regulates Interactions with Exchange Factors, Raf-1 and Phosphoinositide 3-Kinase* , 2002, The Journal of Biological Chemistry.

[17]  A. Kral,et al.  Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. , 2001, Cancer research.

[18]  S. Soignet,et al.  A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  J. Blank,et al.  The ups and downs of MEK kinase interactions. , 2001, Cellular signalling.

[20]  J. Urano,et al.  Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant , 2001, Molecular microbiology.

[21]  C. Der,et al.  Ras and Rho regulation of the cell cycle and oncogenesis. , 2001, Cancer letters.

[22]  R. Muschel,et al.  The Ras radiation resistance pathway. , 2001, Cancer research.

[23]  D. Bar-Sagi,et al.  Differential Activation of the Rac Pathway by Ha-Ras and K-Ras* , 2001, The Journal of Biological Chemistry.

[24]  S. Sebti,et al.  The Farnesyltransferase Inhibitor, FTI-2153, Blocks Bipolar Spindle Formation and Chromosome Alignment and Causes Prometaphase Accumulation during Mitosis of Human Lung Cancer Cells* , 2001, The Journal of Biological Chemistry.

[25]  J. Hancock,et al.  Compartmentalization of Ras proteins. , 2001, Journal of cell science.

[26]  C. Erlichman,et al.  Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  M. You,et al.  Alternative splicing of the K-ras gene in mouse tissues and cell lines. , 2001, Experimental lung research.

[28]  R. Muschel,et al.  The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. , 2001, Cancer research.

[29]  C. Toulas,et al.  Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM‐46228 , 2001, International journal of cancer.

[30]  M. Malumbres,et al.  Targeted Genomic Disruption of H-ras and N-ras, Individually or in Combination, Reveals the Dispensability of Both Loci for Mouse Growth and Development , 2001, Molecular and Cellular Biology.

[31]  C. Bowden,et al.  Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.

[32]  M. Piccart-Gebhart,et al.  A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel : a promising combination in patients (pts) with solid tumors , 2001 .

[33]  S. Hahn,et al.  Farnesyltransferase inhibitors. , 2001, Seminars in oncology.

[34]  P. Vaupel,et al.  Treatment resistance of solid tumors: role of hypoxia and anemia. , 2001, Medical oncology.

[35]  F. Tamanoi,et al.  Farnesylated proteins and cell cycle progression , 2001, Journal of cellular biochemistry. Supplement.

[36]  S. Sebti,et al.  Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues , 2000, Expert opinion on investigational drugs.

[37]  G. Prendergast,et al.  Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. , 2000, Seminars in cancer biology.

[38]  R. Muschel,et al.  Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. , 2000, Cancer research.

[39]  W. R. Bishop,et al.  Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules* , 2000, The Journal of Biological Chemistry.

[40]  P. Thall,et al.  Phase I study of farnesyl tranferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety , 2000 .

[41]  T. Jessell,et al.  RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors , 2000, Molecular and Cellular Biology.

[42]  R. Muschel,et al.  Farnesyltransferase Inhibitors Potentiate the Antitumor Effect of Radiation on a Human Tumor Xenograft Expressing Activated HRAS1 , 2000, Radiation research.

[43]  H. Horstmann,et al.  Prenylation-dependent Association of Protein-tyrosine Phosphatases PRL-1, -2, and -3 with the Plasma Membrane and the Early Endosome* , 2000, The Journal of Biological Chemistry.

[44]  R. Muschel,et al.  RAS-Mediated Radiation Resistance is not Linked to MAP Kinase Activation in Two Bladder Carcinoma Cell Lines , 2000, Radiation research.

[45]  A. Wolfman,et al.  Endogenous c-N-Ras Provides a Steady-state Anti-apoptotic Signal* , 2000, The Journal of Biological Chemistry.

[46]  S. Sebti,et al.  Both Farnesylated and Geranylgeranylated RhoB Inhibit Malignant Transformation and Suppress Human Tumor Growth in Nude Mice* , 2000, The Journal of Biological Chemistry.

[47]  R. Diehl,et al.  Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. , 2000, Cancer research.

[48]  P. Dent,et al.  Ionizing Radiation-Induced Mitogen-Activated Protein (MAP) Kinase Activation in DU145 Prostate Carcinoma Cells: MAP Kinase Inhibition Enhances Radiation-Induced Cell Killing and G2/M-Phase Arrest , 2000 .

[49]  C. Der,et al.  The Ras branch of small GTPases: Ras family members don't fall far from the tree. , 2000, Current opinion in cell biology.

[50]  H. Mellor,et al.  Regulation of endocytic traffic by rho family GTPases. , 2000, Trends in cell biology.

[51]  D. Coppola,et al.  The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis , 2000, Molecular and Cellular Biology.

[52]  W. R. Bishop,et al.  The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo , 2000, Cancer Chemotherapy and Pharmacology.

[53]  H. Scher,et al.  A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility , 2000, Cancer Chemotherapy and Pharmacology.

[54]  A. Guha,et al.  Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects , 1999, Oncogene.

[55]  N. Kohl.  Farnesyltransferase Inhibitors: Preclinical Development , 1999 .

[56]  M. Serrano,et al.  The downregulation of the pro‐apoptotic protein Par‐4 is critical for Ras‐induced survival and tumor progression , 1999, The EMBO journal.

[57]  I. Pollack,et al.  Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model. , 1999, Neurosurgery.

[58]  G. Prendergast,et al.  Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. , 1999, Cancer research.

[59]  G. Favre,et al.  Inhibition of human tumor cell growth In vitro and In vivo by a specific inhibitor of human farnesyltransferase: BIM‐46068 , 1999, International journal of cancer.

[60]  S. Sebti,et al.  Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. , 1999, Cancer research.

[61]  S. Ng,et al.  Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. , 1999, European journal of cancer.

[62]  Zhimin Lu,et al.  RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases , 1999, Oncogene.

[63]  R. Klemke,et al.  Four Human Ras Homologs Differ in Their Abilities to Activate Raf-1, Induce Transformation, and Stimulate Cell Motility* , 1999, The Journal of Biological Chemistry.

[64]  G. Prendergast,et al.  Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB , 1999, Molecular and Cellular Biology.

[65]  R. Wolthuis,et al.  Ras caught in another affair: the exchange factors for Ral. , 1999, Current opinion in genetics & development.

[66]  B. Fenton,et al.  Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements , 1999, British Journal of Cancer.

[67]  J. Urano,et al.  Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[68]  M. Wigler,et al.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Walter A. Korfmacher,et al.  Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. , 1998, Cancer research.

[70]  G. Prendergast,et al.  Non-Ras targets of farnesyltransferase inhibitors: focus on Rho , 1998, Oncogene.

[71]  J. Hancock,et al.  Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase* , 1998, The Journal of Biological Chemistry.

[72]  N. Rosen,et al.  A Farnesyl-Protein Transferase Inhibitor Induces p21 Expression and G1 Block in p53 Wild Type Tumor Cells* , 1998, The Journal of Biological Chemistry.

[73]  M. Wigler,et al.  Signaling pathways in Ras-mediated tumorigenicity and metastasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[74]  I. Pollack,et al.  Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. , 1998, Neurosurgery.

[75]  R. Muschel,et al.  Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. , 1998, Cancer research.

[76]  M. Malumbres,et al.  Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. , 1998, Cancer research.

[77]  S. Sebti,et al.  Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts , 1998, Oncogene.

[78]  N. Rosen,et al.  Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[79]  M. Gelb,et al.  Protein prenylation: from discovery to prospects for cancer treatment. , 1998, Current opinion in chemical biology.

[80]  D. Troyer,et al.  A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis , 1998, Molecular and Cellular Biology.

[81]  R. Kucherlapati,et al.  K-ras is an essential gene in the mouse with partial functional overlap with N-ras. , 1997, Genes & development.

[82]  D M Leonard,et al.  Ras farnesyltransferase: a new therapeutic target. , 1997, Journal of medicinal chemistry.

[83]  Jun Miyoshi,et al.  K-Ras is essential for the development of the mouse embryo , 1997, Oncogene.

[84]  C. Der,et al.  Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? , 1997, Biochimica et biophysica acta.

[85]  P. Casey,et al.  Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB* , 1997, The Journal of Biological Chemistry.

[86]  M. Lewis,et al.  Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo * , 1997, The Journal of Biological Chemistry.

[87]  W. R. Bishop,et al.  K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors* , 1997, The Journal of Biological Chemistry.

[88]  W. R. Bishop,et al.  Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I* , 1997, The Journal of Biological Chemistry.

[89]  G. Prendergast,et al.  Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. , 1997, Cancer research.

[90]  D. Crowell,et al.  Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. , 1996, Cancer letters.

[91]  Jonathan A. Cooper,et al.  TC21 causes transformation by Raf-independent signaling pathways , 1996, Molecular and cellular biology.

[92]  N. Sheibani,et al.  Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. , 1996, Cancer letters.

[93]  S. Sebti,et al.  Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs. , 1996, Biochemical Society transactions.

[94]  M. Wigler,et al.  A Role for the Ral Guanine Nucleotide Dissociation Stimulator in Mediating Ras-induced Transformation* , 1996, The Journal of Biological Chemistry.

[95]  M. Wigler,et al.  Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation , 1996, Molecular and cellular biology.

[96]  T. Urano,et al.  Ral‐GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation. , 1996, The EMBO journal.

[97]  R. Muschel,et al.  Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: influence of H-ras on the G2 delay. , 1996, Oncogene.

[98]  N. Rosen,et al.  A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. , 1995, Cancer research.

[99]  T. Nagasu,et al.  Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. , 1995, Cancer research.

[100]  B. Kaina,et al.  The Ras-related Small GTP-binding Protein RhoB Is Immediate-early Inducible by DNA Damaging Treatments (*) , 1995, The Journal of Biological Chemistry.

[101]  R. Kerbel,et al.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.

[102]  C. Koch,et al.  Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. , 1995, British Journal of Cancer.

[103]  N. Kohl,et al.  Pseudodipeptide inhibitors of protein farnesyltransferase. , 1995, Journal of medicinal chemistry.

[104]  A. Kral,et al.  Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice , 1995, Nature Medicine.

[105]  M. Barbacid,et al.  Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation. , 1995, Oncogene.

[106]  M. Barbacid,et al.  Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. , 1995, Oncogene.

[107]  R. Kucherlapati,et al.  The murine N-ras gene is not essential for growth and development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[108]  R. Taub,et al.  PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth , 1994, Molecular and cellular biology.

[109]  P. D’Eustachio,et al.  Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation , 1994, Molecular and cellular biology.

[110]  M. Lewis,et al.  Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. , 1993, The Journal of biological chemistry.

[111]  F. Tamanoi,et al.  Inhibitors of Ras farnesyltransferases. , 1993, Trends in biochemical sciences.

[112]  A. Levinson,et al.  Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. , 1993, Science.

[113]  R L Smith,et al.  Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. , 1993, Science.

[114]  C J Marshall,et al.  Post-translational modifications of p21rho proteins. , 1992, The Journal of biological chemistry.

[115]  P. Bentvelzen,et al.  Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line. , 1992, Cancer research.

[116]  D. Russell,et al.  cDNA cloning and expression of the peptide-binding β subunit of rat p21rasfarnesyltransferase, the counterpart of yeast DPR1/RAM1 , 1991, Cell.

[117]  J. Hancock,et al.  Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K‐ras(B). , 1991, The EMBO journal.

[118]  C. Marshall,et al.  A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21 ras to the plasma membrane , 1990, Cell.

[119]  C. Ling,et al.  The role of the H-ras oncogene in radiation resistance and metastasis. , 1990, International journal of radiation oncology, biology, physics.

[120]  C. Der,et al.  Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[121]  C. Ling,et al.  Synergistic effect of the v-myc oncogene with H-ras on radioresistance. , 1990, Cancer research.

[122]  L. Cantley,et al.  Phosphoinositide kinases. , 1990, Biochemistry.

[123]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[124]  J. Hancock,et al.  Post‐translational processing of p21ras is two‐step and involves carboxyl‐methylation and carboxy‐terminal proteolysis. , 1989, The EMBO journal.

[125]  C. Der,et al.  Activation of the cellular proto-oncogene product p21Ras by addition of a myristylation signal. , 1989, Science.

[126]  R. Weichselbaum,et al.  Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. , 1989, Science.

[127]  M. Sklar.  The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. , 1988, Science.

[128]  T. Fitzgerald,et al.  Activated human N‐ras oncogene enhances x‐irradiation repair of mammalian cells in vitro less effectively at low dose rate: Implications for increased therapeutic ratio of low dose rate irradiation , 1985, American journal of clinical oncology.

[129]  D. Lowy,et al.  Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. , 1984, The EMBO journal.

[130]  D. Lowy,et al.  The p21 ras C-terminus is required for transformation and membrane association , 1984, Nature.